Interferon a and T-cell responses in chronic myeloid leukemia

REFERENCES

• Clemens MJ. Interferons and apoptosis. J Interferon Cyto-kine Res 2003;23:277 —292.
   Google Scholar
• Espert L, Gongora C, Mechti N. Interferon: antiviral mechanisms and viral escape. Bull Cancer 2003;90:131–141.
   Google Scholar
• Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517 —1536.
   Google Scholar
• Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leu-kemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 1993;82: 2975 —2984.
   Google Scholar
• Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074–3081.
   Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820–825.
   Google Scholar
• Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffier H, Hochhaus A, Heinze B, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994;84:4064 — 4077.
   Google Scholar
• Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906–916.
   Google Scholar
• Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49–61.
   Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, Allan NC, BaccaraniM, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850— 858.
   Google Scholar
• Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003;97:1033–1041.
   Google Scholar
• Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Molecular hetero-geneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000;95:62 — 66.
   Google Scholar
• Chomel JC, Brizard F, Veinstein A, Rivet J, Sadoun A, Kitzis A, Guilhot F, Brizard A. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interfer-on-alpha therapy or allogeneic bone marrow transplantation. Blood 2000;95:404–408.
   Google Scholar
• Mahon FX, Delbrel X, Cony-Makhoul P, Faberes C, Boiron JM, Barthe C, Bilhou-Nabera C, Pigneux A, Marit G, Reiffers J. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Chin Oncol 2002;20:214–220.
   Google Scholar
• Yanagisawa K, Yamauchi H, Kaneko M, Kohno H, Hasegawa H, Fujita S. Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha. Blood 1998;91:641 — 648.
   Google Scholar
• Andrews DF 3rd, Singer JW, Collins SJ. Effect of recombi-nant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines. Cancer Res 1987;47:6629 — 6632.
   Google Scholar
• Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996;88:1635–1644.
   Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041–2050.
   Google Scholar
• den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VI-I et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476–1480.
   Google Scholar
• den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL, Reinhardus C, Shabanowitz J, Offringa R, Hunt DF, Engelhard Vii, Goulmy E. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998;279:1054–1057.
   Google Scholar
• Tseng LH, Lin MT, Hansen JA, Gooley T, Pei J, Smith AG, Martin EG, Petersdorf EW, Martin PJ. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1999;94: 2911–2914.
   Google Scholar
• Akatsuka Y, Warren EH, Gooley TA, Brickner AG, Lin MT, Hansen JA, Martin PJ, Madtes DK, Engelhard Vii, Takahashi T, Riddell SR. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol 2003;123: 671 —675.
   Google Scholar
• Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, Gratwohl A, Vogelsang GB, van Houwelingen HC, van Rood JJ. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281–285.
   Google Scholar
• Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden 0, Rozman C, Speck B, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–562.
   Google Scholar
• Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529–1533.
   Google Scholar
• Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompat-ibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999;5:839 —842.
   Google Scholar
• Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;87:3587 —3592.
   Google Scholar
• Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Chin Invest 1998;101: 2290–2296.
   Google Scholar
• Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, DuvalM, Lemonnier F, Vilmer E, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 1998; 102:455–462.
   Google Scholar
• Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifi-cally recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocy-tic leukemia cells. Blood 1993;81: 1369–1375.
   Google Scholar
• Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6: 405–409.
   Google Scholar
• Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8( +) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95: 286–293.
   Google Scholar
• Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, Stauss HJ. Selective elimination of leukemic CD34( +) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95: 2198–2203.
   Google Scholar
• Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaen-der V, Baerwolf S, Nagorsen D, Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100: 2132–2137.
   Google Scholar
• Molldrem jj, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, Agarwala V, Barrett AJ. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferen-tially inhibit chronic myeloid leukemia colony-forming units. Blood 1997;90:2529–2534.
   Google Scholar
• Fujiwara H, El Ouriaghli F, Grube M, Price DA, Rezvani K, Gostick E, Sconocchia G, Melenhorst J, Hensel N, Douek DC, Barrett AJ. Identification and in vitro expansion of CD4 + and CD8 + T cells specific for human neutrophil elastase. Blood 2004;103:3076–3083.
   Google Scholar
• Anderson G, Moore NC, Owen JJ, Jenkinson EJ. Cellular interactions in thymocyte development. Annu Rev Immunol 1996;14:73–99.
   Google Scholar
• Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998; 280:243–248.
   Google Scholar
• Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, SteinmanL, Rothbard JB. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986; 324:258–260.
   Google Scholar
• Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 1989;59:247–255.
   Google Scholar
• Gaur A, Boehme SA, Chalmers D, Crowe PD, Pahuja A, Ling N, Brocke S, Steinman L, Conlon PJ. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J Neuroimmunol 1997;74:149–158.
   Google Scholar
• Liblau RS, Tisch R, Shokat K, Yang X, Dumont N, Goodnow CC, McDevitt HO. Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Proc Natl Acad Sci USA 1996;93:3031–3036.
   Google Scholar
• Anderton SM, Radu CG, Lowrey PA, Ward ES, Wraith DC. Negative selection during the peripheral immune response to antigen. J Exp Med 2001;193:1–11.
   Google Scholar
• Seamons A, Sutton J, Bai D, Baird E, Bonn N, Kafsack BF, Shabanowitz J, Hunt DF, Beeson C, Goverman J. Competi-tion between two MHC binding registers in a single peptide processed from myelin basic protein influences tolerance and susceptibility to autoimmunity. J Exp Med 2003;197:1391–1397.
   Google Scholar
• Molldrem jj, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018–1023.
   Google Scholar
• Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Muller MC, Berg T, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (5TI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101:259–264.
   Google Scholar
• Franssen CF, Tervaert JW, Stegeman CA, Kallenberg CG. c-ANCA as a marker of Wegener's disease. Lancet 1996;347:116; author reply 118.
   Google Scholar
• Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ, Tervaert JW. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int 2000; 57:2195–2206.
   Google Scholar
• Brouwer E, Stegeman CA, Huitema MG, Limburg PC, Kallenberg CG. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Chin Exp Immunol 1994;98: 448–453.
   Google Scholar
• Williams RC Jr, Staud R, Malone CC, Payabyab J, Byres L, Underwood D. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J Immunol 1994;152:4722–4737.
   Google Scholar
• Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Chin Invest 2003;111:639–647.
   Google Scholar
• Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, Elliott T, Hengartner H, Zinkernagel R. Induction and exhaustion of lymphocy-tic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class 1-peptide complexes. J Exp Med 1998;187:1383–1393.
   Google Scholar
• Wu CJ, Yang XF, McLaughlin S, Neuberg D, Canning C, Stein B, Alyea EP, Soiffer RJ, Dranoff G, Ritz J. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Chin Invest 2000;106:705–714.
   Google Scholar
• Kluin-Nelemans HC, Kester MG, van deCorput L, Boor PP, Landegent JE, van Dongen JJ, Willemze R, Falkenburg JR. Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia. Blood 1998;91:4224–4231.
   Google Scholar
• Kaklamanis L, Gatter KC, Hill AB, Mortensen N, Harris AL, Krausa P, McMichael A, Bodmer JG, Bodmer WF. Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer 1992;51: 379–385.
   Google Scholar
• Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994;83:793–798.
   Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734–738.
   Google Scholar
• Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200–205.
   Google Scholar
• Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998;95: 1178–1183.
   Google Scholar
• Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677 —685.
   Google Scholar
• Hiroishi K, Tuting T, Lotze MT. IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 2000;164:567 — 572.
   Google Scholar
• Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ral-pha, c-myc, and pim-1 genes in human T cells. Blood 199993:1980-1991.
   Google Scholar
• Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999;189:521 —530.
   Google Scholar
• Lombardi G, Dunne PJ, Scheel-Toellner D, Sanyal T, PillingD, Taams LS, Life P, Lord JM, Salmon M, Akbar AN. Type 1 IFN maintains the survival of anergic CD4 + T cells. J Immunol 2000;165: 3782 — 3789.
   Google Scholar
• Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998;64:358–367.
   Google Scholar
• Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161:1947–1953.
   Google Scholar
• Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, Tough DF. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002;99:3263— 3271.
   Google Scholar
• Chakrabarti D, Hultgren B, Stewart TA. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 1996;157: 522 — 528.
   Google Scholar
• Gabriele L, Borghi P, Rozera C, Sestili P, Andreotti M, Guarini A, Montefusco E, Foa R, Belardelli F. IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 2004;103:980 — 987.
   Google Scholar
• Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, OliveD, Gaugler B. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potentfunctional activities. J Immunol 2003;171:3385— 3393.
   Google Scholar
• Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, Arienti F, Belardelli F, Parmiani G, Rivoltini L. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8 + T cell responses against human tumor antigens. J Immunol 2004;172:5363 — 5370.
   Google Scholar
• Yasukawa M, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, Hirai H, Fujita S. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4( + ) T lymphocytes. Blood 2001;98:1498–1505.
   Google Scholar
• Braun MG, Csernok E, Gross WL, Muller-Hermelink HK. Proteinase 3, the target antigen of anticytoplasmic antibodies circulating in Wegener's granulomatosis. Immunolocaliza-don in normal and pathologic tissues. Am J Pathol 1991;139: 831 — 838.
   Google Scholar
• Yang JJ, Pendergraft WF, Alcorta DA, Nachman PH, Hogan SL, Thomas RP, Sullivan P, Jennette JC, Falk RJ, Preston GA. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and mono-cytes of patients with antineutrophil cytoplasmic auto-antibody-associated glomerulonephritis. J Am Soc Nephrol 2004;15:2103–2114.
   Google Scholar
• Trial J, Rubio JA, Birdsall HH, Rodriguez-Barradas M, Rossen RD. Monocyte activation by circulating fibronectin fragments in HIV-1-infected patients. J Immunol 2004;173: 2190–2198.
   Google Scholar
• Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differ-ential gene expression. Am J Pathol 2002;160:641— 654.
   Google Scholar
• Just J, Moog-Lutz C, Houzel-Charavel A, Canteloup S, Grimfeld A, Witko-Sarsat V, Cayre YE. Proteinase 3 mRNA expression is induced in monocytes but not in neutrophils of patients with cystic fibrosis. FEBS Lett 1999; 457:437–440.
   Google Scholar
• Zhou Z, Richard C, Menard HA. De novo synthesis of proteinase 3 by cytokine primed circulating human poly-morphonuclear neutrophils and mononuclear cells. J Rheumatol 2000;27: 2406— 2411.
   Google Scholar
• Kontsek P, Karayianni-Vasconcelos G, Kontsekova E. The human interferon system: characterization and classification after discovery ofnovel members. Acta Virol 2003;47:201 —215.
   Google Scholar
• Driggers PH, Ennist DL, Gleason SL, Mak WH, Marks MS, Levi BZ, Flanagan JR, Appella E, Ozato K. An interferon gamma-regulated protein that binds the interfer-on-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1990;87: 3743 — 3747.
   Google Scholar
• Weisz A, Marx P, Sharf R, Appella E, Driggers PH, Ozato K, Levi BZ. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J Biol Chem 1992;267:25589 — 25596.
   Google Scholar
• Nelson N, Kanno Y, Hong C, Contursi C, Fujita T, Fowlkes BJ, O'Connell E, Hu-Li J, Paul WE, Jankovic D, Sher AF, et al. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J Immunol 1996;156: 3711— 3720.
   Google Scholar
• Holtschke T, Lohler J, Kanno Y, Fehr T, these N, Rosenbauer F, Lou J, Knobeloch KP, Gabriele L, Waring JF, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996;87:307 — 317.
   Google Scholar
• Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring JF, Rosenbauer F, Huhn D, Wittig B, Horak I, Neubauer A. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998;91:22–29.
   Google Scholar
• Burchert A, Cai D, Hofbauer LC, Samuelsson MK, Slater EP, Duyster J, Ritter M, Hochhaus A, Muller R, Eilers M, et al. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bc1-2. Blood 2004;103:3480–3489.
   Google Scholar
• Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood 2001;97: 3648–3650.
   Google Scholar
• Schmidt M, Hochhaus A, Konig-Merediz SA, Brendel C, Proba J, Hoppe GJ, Wittig B, Ehninger G, Hehlmann R, Neubauer A. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. J Clin Oncol 2000;18: 3331— 3338.
   Google Scholar
• Hochhaus A, Yan XH, Willer A, Hehlmann R, Gordon MY, Goldman JM, Melo JV. Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia. Leukemia 1997;11:933 — 939.
   Google Scholar
• Schultheis B, Carapeti-Marootian M, Hochhaus A, Weisser A, Goldman JM, Melo JV. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 200299:1766-1775.
   Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Cer-vantes F, Barrios M, Colomer D, Heiniger A, Torres A. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica 2004;89:42 —48.
   Google Scholar
• O'Brien SG, Guilhot F, Larson RA, Gathmann I, BaccaraniM, Cervantes F, Cornelissen jj, Fischer T, Hochhaus A, Hughes T, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   Google Scholar
• Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadel-phia-positive stem cells from patients with chronic myeloid leukemia are insensitive to 5TI571 in vitro. Blood 2002;99: 319–325.
   Google Scholar
• Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (5TI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased prolifera-rion. Blood 2002;99:3792–3800.
   Google Scholar
• Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell prolifera-tion in vitro and delayed-type hypersensitivity in vivo. Blood 2004;104:1094— 1099.
   Google Scholar
• Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brum-mendorf TH, Brossart P. Imatinib mesylate affects the development and function of dendritic cells generated from CD34 + peripheral blood progenitor cells. Blood 2004;103: 538— 544.
   Google Scholar
• Taieb J, Maruyama K, Borg C, Terme M, Zitvogel L. Imatinib mesylate impairs F1t3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 2004;103: 1966— 1967;author reply 1967.
   Google Scholar